The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
about
Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectivesEpigenetic regulators and their impact on therapy in acute myeloid leukemiaMechanisms of epigenetic regulation of leukemia onset and progressionRecent progress toward epigenetic therapies: the example of mixed lineage leukemiaEmerging concepts of epigenetic dysregulation in hematological malignanciesChromatin-regulating proteins as targets for cancer therapy.Accelerating cancer modeling with RNAi and nongermline genetically engineered mouse models.Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinomaEnhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cellsMutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancersSelective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemiaTwo decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells.Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler.Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2aTargeting EZH2 and PRC2 dependence as novel anticancer therapy.Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic LeukemiaOxidants, antioxidants and the current incurability of metastatic cancers.The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.Transcription factor RUNX1 promotes survival of acute myeloid leukemia cellsGenomic characterization of childhood acute lymphoblastic leukemia.Epigenetics in cancer stem cells.MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.In focus: MLL-rearranged leukemia.The controversial role of the Polycomb group proteins in transcription and cancer: how much do we not understand Polycomb proteins?Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.Epigenetic modifiers in normal and malignant hematopoiesis.Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase.CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.Inhibitors of Protein Methyltransferases and Demethylases.Collaboration of MLLT1/ENL, Polycomb and ATM for transcription and genome integrity.Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domainsRole of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer.H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.
P2860
Q26744441-A26F5129-F2FC-4391-8006-9E93C0F16C67Q26765402-37898143-6599-47CA-B10A-A1377C01FFD3Q26861785-6D646D46-3B6D-42AE-ACFE-3F8329757119Q26863577-5CCE36DE-AD3B-49D3-B403-7F1CDBE3E2F9Q28074522-A7A1BBB7-4E9B-4115-8C7D-AB506A4B4AFFQ33907067-1C12E05E-C4AF-425D-BEE4-545E3F99991DQ33914682-5281A595-B452-4FBC-B857-D039C98C1B96Q34287415-61C3EF5C-917A-4174-8214-819A74A40DA0Q34380688-D5C4E89A-4387-45C8-8728-1727A80AE48EQ34651312-43978A05-975F-4F93-BFCA-F08777E3BE2FQ34861658-E984107F-E9D6-4347-BAB3-9D33C8025FC0Q34876825-C757C967-02B5-4B0E-B486-076717CC601BQ35018755-E6A7076F-1E54-49E6-B7BA-745693E7E7C0Q35686509-CCD68D80-02CE-49A5-A0AF-C0D8F93B3E03Q36288331-A1FECF97-2EA3-4CCE-B920-0E1FD7932249Q36395823-1040054A-1826-42E0-8B10-0BB4D00856EEQ36432056-DF1C544E-AAEC-417A-BCF0-2824AB1E7B60Q36445523-21A9DACF-5E53-4B20-9058-C791BBBF30BBQ36518228-51151950-D9BF-4A18-955E-66098812409EQ36673042-BDD488D4-E094-4643-8576-FC05169CA66CQ36682938-318B959A-CB59-428A-B07C-23817F7E00ABQ36702422-980B5669-A569-42B2-A360-40BCCB944D49Q36892595-C434F438-0859-4ED5-B3B2-71BDC2BC866EQ37038076-EB3A05FF-D7D4-41BD-B90C-0C445B5A8E36Q37123913-D615E5CD-217B-44A5-A675-D3E42440568CQ37359118-2F412858-F6A5-4F6C-AE09-407D6CB77EC9Q37618640-42BD86C6-FF72-4F70-8C8D-7A9485B312C1Q37633585-63724F3A-6AFA-4A3F-9DAD-CA97DE6BAED5Q37699211-A66A9FC8-4AD0-4119-8765-607BC19D3F36Q38091585-1AD1109B-C433-4A63-8B21-17BC57CBCC01Q38260253-6FA79E3D-32F1-4C96-AEEC-5EA99415F290Q38429500-C51EB460-7DEE-4ADE-8023-F37A882ADBB0Q38459868-F3F7C3A8-65CF-452E-BC14-EAB8C8CDD366Q38698037-3338D6DC-C4A0-409B-AE58-E3FEFFCDC56DQ38727999-3A9CB372-8E70-474A-9C74-37C6FD29194FQ38740496-A9EF2A84-98B2-4138-8E5A-B0980E2845AFQ38867022-78B9EA20-94BE-447A-B2E2-746602EF1594Q38876767-03DB04B1-4018-4B7D-89A4-C896B71A80AAQ38906194-65D4DEE1-5A95-4856-887D-D21C011E564DQ38906678-85784D66-0A1C-4E21-925E-6290BBE57231
P2860
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The Polycomb complex PRC2 supp ...... (G12D) acute myeloid leukemia.
@ast
The Polycomb complex PRC2 supp ...... (G12D) acute myeloid leukemia.
@en
type
label
The Polycomb complex PRC2 supp ...... (G12D) acute myeloid leukemia.
@ast
The Polycomb complex PRC2 supp ...... (G12D) acute myeloid leukemia.
@en
prefLabel
The Polycomb complex PRC2 supp ...... (G12D) acute myeloid leukemia.
@ast
The Polycomb complex PRC2 supp ...... (G12D) acute myeloid leukemia.
@en
P2093
P2860
P356
P1433
P1476
The Polycomb complex PRC2 supp ...... s(G12D) acute myeloid leukemia
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2012.110
P407
P577
2012-04-02T00:00:00Z
P6179
1022455288